Hypoglycemic Agents
DrugMultiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
NCT Number: NCT00542178
Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This current study will examine the effects of the ACCORD treatments on the progression of DR in people participating in the ACCORD study.
Looking for future studies?
Notify Me40 year–79 year
All sexes
Interventional
Phase 3
McMaster University, Hamilton, Ontario, Canada
DR is the most common diabetic eye disease and is the leading cause of blindness in adults in the United States. It is caused by damage to the blood vessels of the retina, which is the light-sensitive outer layer of the eye. Retinal blood vessels are often affected by the high blood sugar levels associated with diabetes. Older people have an increased risk of developing DR; however, DR is likely to occur earlier and be more severe in anyone who has poorly controlled diabetes. Almost everyone who has had diabetes for more than 30 years will eventually show signs of DR. Symptoms of DR include poor night vision, seeing spots in front of the eyes, blurred vision, and blindness. The ACCORD study is a study that is examining the effects of different treatments on cardiovascular disease in people with diabetes. Participants in the ACCORD study will receive one of eight different combinations of treatment, including blood sugar control, blood pressure control, and cholesterol-controlling medication. This study will enroll participants in the ACCORD study and will examine the effects of the study treatments on DR. The results from this study may be used to develop new treatments to help prevent diabetes-related blindness.
Study visits will occur at baseline and Year 4. At each study visit, participants will have an eye exam and specialized fundus photographs taken of the back of the eye and retina.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
A strategy of glycemia drugs for HbA1c 7% - 7.9%
A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
A strategy of BP drugs for SBP less than 140 mm Hg
Blinded fenofibrate
Simvastatin 20-40 mg/d
Placebo
Time frame: Measured at Year 4
Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher.
Time frame: Measured at Year 4
Time frame: Measured at Year 4
Time frame: Measured at Year 4
National Heart, Lung, and Blood Institute (NHLBI)
Nih
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00041444
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05282680
Autoimmune Diseases, Brain Diseases
Shatin, Hong Kong
View Trial DetailsNCT05276778
Cardiovascular Diseases, Diabetes Complications
Aalborg, DK, Denmark
View Trial DetailsNCT02662010
Cardiovascular Diseases, Diabetes Complications
Aurora, Colorado, United States
View Trial Details